Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
Biosimilars are safe and effective treatments for chronic diseases such as cancer and rheumatoid arthritis. The Saudi Food and Drug Authority (SFDA) manages the quality and registration of biosimilars in the Kingdom of Saudi Arabia. However, disparities among regulatory authorities, such as the abse...
Saved in:
Main Authors: | Mohammed Alqahtani, Ahmed Al-jedai, Albert Wertheimer |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Minnesota Libraries Publishing
2024-11-01
|
Series: | INNOVATIONS in Pharmacy |
Subjects: | |
Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/6371 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CURRENT APPROACH TO DEVELOPMENT OF BIOSIMILAR PRODUCTS CONTAINING MONOCLONAL ANTIBODIES AS AN ACTIVE SUBSTANCE – NON-CLINICAL AND CLINICAL STUDIES OF THE FIRST RUSSIAN RITUXIMAB BIOSIMILAR, ACELLBIA®
by: S. M. Alekseev, et al.
Published: (2015-04-01) -
Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study
by: Debdulal Chakraborty, et al.
Published: (2025-01-01) -
Biosimilar biological drugs in the treatment of inflammatory bowel diseases
by: Magdalena Kaniewska, et al.
Published: (2019-12-01) -
Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product
by: Neungseon Seo, et al.
Published: (2024-11-01) -
Knowledge on the Use of Biosimilars in Hematological Malignancies Amongst Health Care Workers at a Tertiary Hospital in Northeast Nigeria
by: Rufai A. Dachi, et al.
Published: (2024-07-01)